期刊文献+

乙酰半胱氨酸联合泼尼松治疗特发性肺间质纤维化患者疗效 被引量:13

Effects of acetylcysteine plus prednisone for idiopathic pulmonary fibrosis patients
下载PDF
导出
摘要 目的观察乙酰半胱氨酸联合泼尼松治疗特发性肺间质纤维化(IPF)患者的治疗效果。方法将45例IPF患者随机分为3组,泼尼松组15例(A组),每日(理想体质量)0.5mg/kg,口服4周,然后每日0.25mg/kg,口服8周,继之减量至每日0.125mg/kg口服;小剂量乙酰半胱氨酸组15例(B组),在上述泼尼松治疗基础上加用乙酰半胱氨酸200mg,每日3次;大剂量乙酰半胱氨酸组15例(C组),在上述泼尼松治疗基础上加用大剂量乙酰半胱氨酸600mg,每日3次;疗程6个月。观察治疗前后各组患者肺活量(VC)、6分钟步行试验(6MWT)距离变化,评价总体疗效。结果 3组治疗后VC、6MWT较治疗前均降低。C组疗效好于A组和B组(P<0.05)。C组VC、6MWT较其他治疗组下降缓慢(P<0.05)。结论大剂量乙酰半胱氨酸联合泼尼松能延缓特发性肺间质纤维化患者肺功能下降及6MWT距离的减少。 ABSTRACT:Objective To study the effects of acetylcysteine plus prednisone on idiopathic pulmonary fibrosis (IPF)patients.Methods Forty-five IPF patients were randomly divided into control group 15 cases (treated with prednisone therapy only,group A),low doses of acetylcysteine plus prednisone group 15 cases (acetylcysteine 200 mg per time,3 times a day orally for 6 months,group B)and large doses of acetylcysteine plus prednisone group 15 cases (acetylcysteine 600 mg per time,3 times a day orally for 6 months,group C).The change of clinical symptoms,vital capacity(VC),6 minute walk test distance(6MWT)were observed.Results VC and 6MWT after treatment were significantly lower than before treatment in all three groups.The effects in group C were significantly better than those in group A and B(P 〈0.05).Conclusion High dose acetylcysteine plus prednisone therapy delayed IPF in patients with reduced lung function and decreased in 6 MWT.
出处 《临床荟萃》 CAS 2015年第1期38-40,共3页 Clinical Focus
关键词 特发性肺纤维化 肺活量 乙酰半胱氨酸 idiopathic pulmonary fibrosis vital capacity acetylcysteine
  • 相关文献

参考文献14

  • 1刘景峰,郭静波,赵品,李亮,王坤,武慧娟.中医药治疗肺间质纤维化的进展[J].临床荟萃,2011,26(9):820-824. 被引量:5
  • 2孙永昌,姚婉贞,郑杰,王田力,裴斐,赵鸣武.非特异性间质性肺炎临床放射病理诊断分析[J].中华结核和呼吸杂志,2004,27(10):664-667. 被引量:6
  • 3American Thoracic Society. Idiopathic pulmonary fibrosis:diagnosis and treatment. International statement. AmericanThoracic Society (ATS),and the European Respiratory Society(ERS) [J]. Am J Respir Crit Med,2000,161(2 Ptl) :646-664.
  • 4Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis :evidence-based guidelines for diagnosis and management [ J ].Am j Respir Crit Care Med, 2011,183(6) :788-824.
  • 5Daniil ZD, Gilchrist FC,Nicholson AG, et al. A histologicpattern of nonspecific interstitial pneumonia is associated witha better prognosis than usual interstitial pneumonia in patientswith cryptogenic fibrosing alveolitis[J]. Am J Respir Crit CareMed, 1999,160(3):899-905.
  • 6Bjoraker JA, Ryu JH, Edwin MK, et al. Prognosticsignificance of histopathologic subsets in idiopathic pulmonaryfibrosis[J]. Am J Respir Crit Care Med, 1998, 157(1):199-204.
  • 7Chan AL* Rafii R,Louie S,et al. Therapeutic update inidiopathic pulmonary fibrosis[J]. Clin Rev Allergy Immunol,2013,44(l):65-74.
  • 8Tanjore H,Blackwell TS, Lawson WE. Emerging evidencefor endoplasmic reticulum stress in the pathogenesis ofidiopathic pulmonary fibrosis[J], Am J Physiol Lung Cell MolPhysiol, 2012,302(8) :L721-729.
  • 9Homma S, Azuma A, Taniguchi H,et al. Efficacy of inhaledN-acetylcysteine monotherapy in patients with early stageidiopathic pulmonary fibrosis[J]. Respirology, 2012 ,17(3):467-477.
  • 10Demedts M, Behr J, Buhl R,et aL High-dose acetylcysteinein idiopathic pulmonary fibrosis[J]. N Engl J Med, 2005,353.21) :2229-2242.

二级参考文献36

共引文献9

同被引文献108

引证文献13

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部